PMR Report: Medicines as an OTC segment driver in 2018

Ten post jest także dostępny w języku: polski

According to the latest PMR report, in 2018 the market of OTC drugs and dietary supplements (retail and non-retail sales) reached PLN 13.2bn. The growth rate was higher than in 2017, and the market was driven by the retail sale of OTC drugs. In 2019-2024, the market will grow at an average annual rate of 4%, according to PMR forecasts. In 2018, the dynamics of sales in the OTC pharmaceutical segment was record-breaking over the last few years (except for 2016) and higher than the growth of the entire OTC market.

This was due to the large number of OTC drug trading permits issued, the record-breaking influenza incidence and the Rx-OTC Ketonal switch, which generated several dozen million PLN in sales revenue in 2018. On the other hand, the non-pharmacy segment of OTC drugs recorded another year in a row negative dynamics, where the growth is hampered by the lack of expansion of the list of products admitted to trading. Overall, the segment of OTC drugs (retail and non-pharmacy sales) grew by nearly 6% in 2018, according to PMR’s estimates.

The situation may change if there are changes in the lists of medicines allowed for non-pharmacy sales.More information in PMR’s report: OTC market in Poland 2019. Market analysis and development forecasts for 2019-2024.

Similar Posts

Leave a Reply

Your email address will not be published.